Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition?
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Industry Attractiveness - Porter’s Five Forces Analysis
4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Consumers
4.2.3 Threat of New Entrants
4.2.4 Threat of Substitute Products
4.2.5 Intensity of Competitive Rivalry
4.3 Industry Value Chain Analysis?
4.4 Industry Policies
4.5 Market Drivers
4.5.1 Growing Emphasis on Drug Discovery and Outsourcing of Manufacturing
4.5.2 Strong R&D Investments
4.6 Market Challenges
4.6.1 Presence of Low-Cost Alternatives For Outsourcing
4.6.2 Regulatory & Operational Concerns Due to the Move Towards Serialization
4.7 Key considerations involved in the selection of a CMO in the US?
4.8 Impact of COVID-19 on CMOs and Analysis on the Short & Medium-Term Impact on Manufacturing Output


5 TECHNOLOGY SNAPSHOT


6 MARKET SEGMENTATION
6.1 By Service Type
6.1.1 Active Pharmaceutical Ingredient (API) Manufacturing
6.1.1.1 Small Molecule?
6.1.1.2 Large Molecule?
6.1.1.3 High Potency API (HPAPI)?
6.1.2 Finished Dosage Formulation (FDF) Development and Manufacturing?
6.1.2.1 Solid Dose Formulation?
6.1.2.2 Liquid Dose Formulation?
6.1.2.3 Injectable Dose Formulation?
6.1.3 Secondary Packaging


7 RELATIVE POSITIONING ANALYSIS


8 COMPETITIVE LANDSCAPE
8.1 Key Vendor Profiles
8.1.1 Catalent Inc.
8.1.2 Recipharm AB?
8.1.3 Jubilant Life Sciences Ltd?
8.1.4 Thermo Fisher Scientific Inc. (Patheon Inc.) ?
8.1.5 Boehringer Ingelheim?Group
8.1.6 Pfizer CentreSource (Pfizer Inc.)
8.1.7 Aenova Group
8.1.8 AbbVie Contract Manufacturing
8.1.9 Baxter Biopharma Solutions (Baxter International Inc.)?
8.1.10 Lonza Group AG?
8.1.11 Siegfried AG


9 INVESTMENT ANALYSIS?


10 FUTURE OUTLOOK